



# Revcovi® (elapegademase-lvlr) Prior Authorization and Access Guide



Visit [chiesitotalcare.com](http://chiesitotalcare.com)  
or call 1-866-272-7078 –  
we're ready to help!

### Indication

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

### Important Safety Information

#### Warnings and precautions

- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

#### Adverse reactions

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Rевcovi treatment:

- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas

#### Important monitoring information


Treatment with Rевcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

**Please see accompanying Prescribing Information.**



# Chiesi Total Care<sup>SM</sup> will submit for insurance reimbursement and help you navigate prior authorization (PA).

Here's a step-by-step look at the process



## PA denied? Chiesi Total Care is here to help.

It's not uncommon for the first PA submission to be denied. With a long track record of success in gaining PA and appeal approvals, Chiesi Total Care is here to provide assistance with the appeal process. Chiesi Total Care will assist in providing additional resources and/or publications depending on the reasons for denial. To request a copy of an additional resource or publication, please reach out directly to us.medical@chiesi.com.

Visit [chiesitotalcare.com](https://chiesitotalcare.com) or call  
1-866-272-7078



We provide updates on your patient's therapy and alert the office should there be any concerns. We also help patients with injection support for those who receive Revcovi injections at home.

**We can help by:**

- Providing injection support
- Counseling patients on managing side effects
- Providing 24/7 pharmacist access
- Enrolling patients in the Revcovi Copay Program – patients may pay as little as \$0 if eligible†



Lesa, Chiesi Total Care Pharmacist

† Patients participating in government-funded plans may not participate in programs that provide financial support. Please refer to the full Terms and Conditions in the back pocket for additional eligibility requirements.

**Here is a checklist of best practices for Prior Authorization submission:**

- Include pertinent clinical notes, dates, and laboratory findings including diagnosis confirmation
- Include prescribing practitioner NPI number and contact information
- Include medical rationale for why the patient cannot receive a bone marrow transplant
- Include therapeutic alternatives that were tried in the past, include documentation as to why it was inadequate

**Important monitoring information**

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

**Please see additional Important Safety Information throughout and accompanying full Prescribing Information.**

---

## Indication

Revcovi® (elapegedemase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

## Important Safety Information

### Warnings and precautions

- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

### Adverse reactions

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas

### Important monitoring information

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

**Please see full Prescribing Information inside.**

**References:** 1. Revcovi® (elapegedemase-lvlr) Prescribing Information. Chiesi USA, Inc.; 2020.

For more information, visit [revcovi.com](http://revcovi.com).

Chiesi Total Care<sup>SM</sup> Program offered through EVERSANA Life Science Services Specialty Pharmacy

© CHIESI USA, Inc., 2023. All rights reserved.

Revcovi® is a registered trademark of CHIESI FARMACEUTICI S.p.A.

Chiesi Total Care<sup>SM</sup> is a service mark of CHIESI FARMACEUTICI S.p.A.

PP-RV-0102 V1.0 2023

